All In Biotech

NDA 020325 · Kenvue Brands

Pepcid Ac

Famotidine · Oral · Histamine-2 Receptor Antagonist

Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Apr 28, 1995

Approved uses

3

Original approval plus efficacy supplements

Registered trials

147

23 Phase 3, 15 recruiting

FAERS reports

84,762

56,219 serious, 8,065 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 6, 2026.

Uses relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 23, 2003 Supplement 15 · Efficacy ReviewLabelLetter
  • Nov 9, 1998 Supplement 7 · Efficacy
  • Apr 28, 1995 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • PEPCID AC · FAMOTIDINE 10MG · TABLET, ORAL · Over-the-counter
  • PEPCID AC · FAMOTIDINE 20MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Famotidine" as an intervention, any sponsor and status, largest first.

All 147 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea5,480
  • fatigue5,226
  • diarrhoea5,095
  • chronic kidney disease4,686
  • off label use4,432
  • drug ineffective4,253
  • dyspnoea4,008
  • headache3,755
  • acute kidney injury3,418
  • vomiting3,320
  • pain3,257
  • dizziness3,157

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004743
2005736
2006692
2007679
2008850
2009721
20101,023
20111,563
20121,933
20131,154
20141,431
20152,552
20163,020
20173,301
20184,644
20195,538
20206,658
20216,825
20227,306
20237,406
20248,625
20259,592
20267,766

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 566 on PubMed

Sponsor: Kenvue Brands

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.